Our commitment to innovation in cancer care
Over the past several decades, our innovative medicines have improved how cancer is treated, making long-term survival a possibility for more patients. We strive to help more patients across a broad range of solid tumors and blood disorders with our medicines, scientific discovery and investigational research, and are working with partners to address all aspects of patient care, from diagnosis onward.
Until we can offer each person with cancer a better, healthier life, we will keep working.
Our commitment to the cancer community
We are committed to fostering a community of support, creating awareness about the challenges people living with cancer face, and spearheading initiatives to address disparities in cancer research and care.
A cancer patient has received the first chemo infusion ever given within the country of Lesotho, in part, because of the work of the Bristol Myers Squibb Foundation, an independent charitable organization. Read more about their global impact on access to cancer treatment.
Leadership perspectives on complex topics that affect our science, our medicine and our patients.
Jonathan Cheng, MD, senior vice president, Head of Oncology Development, details how the use of immunotherapy in earlier stages of cancer may help prevent recurrence and improve outcomes for patients.
Anne Kerber, senior vice president, head of Cell Therapy Development, reflects on her desire to deliver life-changing treatments to patients and how this led her from the clinic to the world of drug discovery and development.
Advancing cancer care
Every day we strive to push the boundaries and explore new frontiers in cancer treatment.
Dana Walker, MD, MSCE, vice president and Genitourinary (GU) Cancers Development Lead, sheds light on the importance of ongoing GU cancer research, the unmet needs for patients with GU tumors and where we go from here to offer hope to even more people impacted by cancer.
Abderrahim Oukessou, MD, our vice president and Thoracic Cancers Development Lead, sat down with Adam Schoenfeld, MD, medical oncologist, Memorial Sloan Kettering Cancer Center to discuss how the landscape of lung cancer research has transformed in recent years.
Rod Humerickhouse, MD, PhD, vice president of Hematology Development, Multiple Myeloma, and Rosanna Ricafort, MD, vice president, head of Cellular Therapy Clinical Development, share more about our commitment to the multiple myeloma community and continued progress in advancing treatment for every patient living with this disease.
Scientific and disease-specific resources
View and download infographic resources to learn about a variety of solid and hematologic cancers and new cutting-edge treatment approaches.